Experienced in Gliosarcoma

Dr. Jeanny B. Aragon-Ching

Oncology | Hematology | Hematology Oncology
Inova Health Care Services
3300 Gallows Rd, 
Falls Church, VA 
Accepting New Patients
Offers Telehealth
Experienced in Gliosarcoma
Inova Health Care Services
3300 Gallows Rd, 
Falls Church, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Aragon-Ching is rated as an Experienced provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Her clinical research consists of co-authoring 116 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Inova Alexandria Hospital
Inova Loudoun Hospital
Inova Fair Oaks Hospital
Inova Mount Vernon Hospital
Inova Fairfax Hospital
Languages Spoken
English
Filipino
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Innovation Health
  • HMO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

INOVA HEALTH CARE SERVICES
3300 Gallows Rd, Falls Church, VA 22042
Other Locations
INOVA HEALTH CARE SERVICES
4320 Seminary Rd, Alexandria, VA 22304
INOVA HEALTH CARE SERVICES
3600 Joseph Siewick Dr, Fairfax, VA 22033
INOVA HEALTH CARE SERVICES
8081 Innovation Park Dr, Fairfax, VA 22031

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
Enrollment Status: Terminated
Publish Date: February 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

116 Total Publications

Harnessing genomic profiling for improved Urothelial cancer outcomes.
Harnessing genomic profiling for improved Urothelial cancer outcomes.
Journal: Expert review of anticancer therapy
Published: October 15, 2025
Similar Doctors
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology

American Oncology Partners PA

19520 Doctors Dr, 
Germantown, MD 
 (22.1 miles away)
240-912-7645
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Daya Sharma is an Oncologist and a Hematologist Oncology provider in Germantown, Maryland. Dr. Sharma is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, and Neuroepithelioma. Dr. Sharma is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology
Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology

Medstar Medical Group Ii LLC

18101 Prince Philip Dr, 
Olney, MD 
 (22.5 miles away)
301-570-7404
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Behzad Doratotaj is a Hematologist Oncology specialist and a Hematologist in Olney, Maryland. Dr. Doratotaj is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Oligodendroglioma, Ependymoma, and Embryonal Tumor with Multilayered Rosettes. Dr. Doratotaj is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Mark G. Goldstein
Hematology Oncology | Oncology | Hematology
Advanced in Gliosarcoma
Dr. Mark G. Goldstein
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (12.6 miles away)
301-571-0019
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Goldstein is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Goldstein is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma. Dr. Goldstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aragon-Ching's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile